Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth B Gordon

Showing results (61-70 of 136) with videos related to

Pageof 14
Sort By:
Advances in Therapy|November 22, 2019
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated AnalysisGerd R Burmester, Kenneth B Gordon, James T Rosenbaum, et al.
Archives of Dermatology|June 22, 2005
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysisAdam M Quinn, Kimberly Brown, Brian K Bonish, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|October 31, 2006
Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammationBrian J Nickoloff, Brian K Bonish, Deborah J Marble, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsKenneth B Gordon, Keith A Betts, Murali Sundaram, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|December 11, 2002
Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgerySharon Gohari, Charles Gambla, Mary Healey, et al.
JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.
The Journal of Clinical and Aesthetic Dermatology|October 30, 2013
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm MeetingAndrew Blauvelt, Marc Brown, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
Pageof 14

Showing results (61-70 of 136) with videos related to

Sort By:
Pageof 14
Advances in Therapy|November 22, 2019
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated AnalysisGerd R Burmester, Kenneth B Gordon, James T Rosenbaum, et al.
Archives of Dermatology|June 22, 2005
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysisAdam M Quinn, Kimberly Brown, Brian K Bonish, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|October 31, 2006
Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammationBrian J Nickoloff, Brian K Bonish, Deborah J Marble, et al.
American Journal of Clinical Dermatology|September 10, 2020
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 StudyKristian Reich, April W Armstrong, Peter Foley, et al.
Journal of the American Academy of Dermatology|March 9, 2025
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 studyKenneth B Gordon, Matthias Augustin, Jonathan Barker, et al.
Journal of the American Academy of Dermatology|October 11, 2017
Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trialsKenneth B Gordon, Keith A Betts, Murali Sundaram, et al.
Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]|December 11, 2002
Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgerySharon Gohari, Charles Gambla, Mary Healey, et al.
JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.
The Journal of Clinical and Aesthetic Dermatology|October 30, 2013
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm MeetingAndrew Blauvelt, Marc Brown, Kenneth B Gordon, et al.
Journal of the American Academy of Dermatology|January 7, 2017
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trialKristian Reich, April W Armstrong, Peter Foley, et al.
Pageof 14